
Managing GLP-1 Side Effects: Practical Strategies
Nausea and other gastrointestinal effects are common, but persistent or severe symptoms should not be dismissed as the medicine working. Assessment and dose decisions belong with the prescriber.
At a glance
- Track symptom timing, food and fluid intake, and recent dose changes.
- Persistent severe abdominal pain or an inability to keep fluids down needs prompt assessment.
- A delayed-emptying effect does not itself establish a diagnosis of gastroparesis.
Describe the symptom instead of guessing the cause
Record what happens, when it began, whether there was a dose change and whether eating, drinking or bowel movements are affected. Other medicines and illnesses can cause similar symptoms.
Smaller tolerable meals and avoiding foods that worsen symptoms may help with mild nausea. A clinician should decide whether treatment needs to be paused or changed rather than expecting someone to endure escalating symptoms.
Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information
Where self-management ends
Severe or persistent abdominal pain, repeated vomiting, fainting or signs of dehydration can require urgent medical care. Product labels include warnings for pancreatitis, gallbladder problems, volume depletion and severe gastrointestinal reactions.
Do not diagnose gastroparesis from nausea alone. It requires clinical evaluation. The labels advise against use in severe gastroparesis, and preexisting stomach problems belong in the initial assessment.
Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information
Make the contact pathway clear before starting
Ask who responds to symptoms, how quickly clinical questions are reviewed and what to do after hours. A fulfillment or customer-support team is not necessarily the clinician who can change the prescription.
Do not increase a dose to follow a fixed calendar when tolerance is poor. A longer interruption also requires a discussion of safe restarting.
Sources: Wegovy prescribing informationZepbound prescribing informationFoundayo prescribing information
Sources and review boundaries
Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.
- Wegovy prescribing informationMedical or regulatory source · Source reviewed ·
- Zepbound prescribing informationMedical or regulatory source · Source reviewed ·
- Foundayo prescribing informationMedical or regulatory source · Source reviewed ·
A closer look at the research
Read the definitions and study methods behind the headline, with original figures and downloadable study data.
- Semaglutide safety headlines: what does a severe-event percentage measure?
How measurement definitions and analysis choices shape the meaning of a semaglutide safety headline.
- Tirzepatide discontinuation: when stopping treatment and leaving a study differ
The meaning of a stopping percentage depends on the event definition, the people counted and the observation that continues afterward. An evidence-focused reading of tirzepatide research.
Related Articles
GLP-1 medicines before surgery: what to tell the anesthesia team
Tell the anesthesia and procedural team about GLP-1 use early. Current multisociety guidance calls for an individualized plan rather than a blanket stop rule.
What to do when a GLP-1 shipment arrives warm
If an injectable medicine arrives warm, damaged or without clear instructions, contact the pharmacy before using it. The product and actual shipping conditions matter.
Alcohol on semaglutide: risks and questions for your prescriber
There is no alcoholic drink proven safest on a GLP-1. Alcohol can complicate nausea, hydration, blood sugar and the health conditions being treated.
Alcohol on tirzepatide: risks and questions for your prescriber
There is no alcoholic drink proven safest on a GLP-1. Alcohol can complicate nausea, hydration, blood sugar and the health conditions being treated.
Semaglutide compounding pharmacies: sourcing, rules and open questions
Compounded semaglutide and tirzepatide are not FDA-approved. Resolved shortages changed the basis for routine copies, and a pharmacy registration is not approval of its product.
Tirzepatide compounding pharmacies: sourcing, rules and open questions
Compounded semaglutide and tirzepatide are not FDA-approved. Resolved shortages changed the basis for routine copies, and a pharmacy registration is not approval of its product.
By Chief Medical Correspondent. Original publication date was not recorded. Updates are recorded when content changes.